0.18
+0.0042(+2.35%)
Currency In USD
| Previous Close | 0.18 |
| Open | 0.17 |
| Day High | 0.2 |
| Day Low | 0.18 |
| 52-Week High | 1.8 |
| 52-Week Low | 0.13 |
| Volume | 3.26M |
| Average Volume | 1.78M |
| Market Cap | 22.83M |
| PE | -0.12 |
| EPS | -1.51 |
| Moving Average 50 Days | 0.62 |
| Moving Average 200 Days | 0.9 |
| Change | 0 |
If you invested $1000 in Vor Biopharma Inc. (VOR) since IPO date, it would be worth $4.87 as of May 22, 2025 at a share price of $0.183. Whereas If you bought $1000 worth of Vor Biopharma Inc. (VOR) shares 3 years ago, it would be worth $41.62 as of May 22, 2025 at a share price of $0.183.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
GlobeNewswire Inc.
May 08, 2025 12:30 PM GMT
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundra
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
GlobeNewswire Inc.
Mar 20, 2025 8:05 PM GMT
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025$55.6 mil
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
GlobeNewswire Inc.
Feb 13, 2025 1:00 PM GMT
Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trialsDespite the increased time required to obt